|
|
||||||||
Department of Nuclear Medicine, Istituto S. Raffaele, Milan, Italy
Correspondence: For reprints contact: P. Gerundini, MD, Servizio di Medicina Nucleare, Istituto S. Raffaele, Via Olgettina 60, 20132 Milano, Italy.
ABSTRACT
Over the past 15 years a major goal of research in cardiovascular nuclear medicine has been the development of 99mTc complexes that could replace 201TI and thus enhance the utility of myocardial perfusion imaging. This paper presents an overview of the current state-of-art of the development of cationic 99mTc complexes for this purpose. Cationic 99mTc complexes that have been evaluated as myocardial perfusion imaging agents in human volunteers and/or animals are discussed and classified on the basis of the oxidation state of the technetium center.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |